SUMMARY -Herpes group viruses (herpes simplex virus, HSV; varicella-zoster virus, VZV; cytomegalovirus, CMV; and Epstein-Barr virus, EBV) remain an important cause of morbidity in immunocompromised persons. Th e aim of the study was to analyze the prevalence of HSV-1, HSV-2, VZV, CMV and EBV in patients undergoing hemodialysis. During a three-year period (2013)(2014)(2015), 152 consecutive serum samples from hemodialysis patients and 150 healthy subjects (control group) were tested for the presence of IgM/IgG antibodies to herpes group viruses. Serologic tests were performed using a commercial enzyme-linked immunosorbent assay (ELISA) or enzyme-linked immunofl uorescent assay (ELFA). Hemodialysis patients showed signifi cantly higher CMV IgG seropositivity compared to controls (88.2% vs. 78.7%, p=0.011). In addition, seroprevalence rates of HSV-1 and VZV were higher in hemodialysis patients; however, these diff erences did not reach statistical signifi cance (85.5% vs. 80.0%, p=0.054 and 99.3% vs. 96.0%, p=0.051, respectively). Th e prevalence of HSV-2 and EBV was similar in both groups (12.5% vs. 12.7%, p=0.137 and 98.0% vs. 95.3%, p=0.113, respectively). Th ere was no diff erence in IgG seropositivity according to gender and place of residence. Logistic regression showed that older age was a signifi cant predictor for CMV and EBV IgG seropositivity (increase in age by one year: CMV OR=1.055; 95%CI=1.030-1.080 and EBV OR=1.075, 95%CI=1.023-1.130).
Introduction
Members of the herpesvirus family including herpes simplex virus (HSV) type 1 and 2, varicella-zoster virus (VZV), cytomegalovirus (CMV) and EpsteinBarr virus (EBV) are distributed worldwide. Prevalence rates vary signifi cantly among regions and population groups 1, 2 . Herpesviruses are usually spread by direct contact with infected saliva (HSV, CMV and EBV). VZV is the exception and is spread by airborne transmission, while sexual transmission is important for HSV type 2 and CMV 3 . Moreover, herpesviruses can be transmitted by blood transfusion and organ transplantation 4 . Th e unique feature of these viruses is the ability to establish a latent, nonproductive infection with the life-long capacity for reactivation to productive, lytic infection 1 . In immunocompetent persons, primary infections are usually asymptomatic or presented as mild, selflimited disease, i.e. gingivostomatitis or blisters (HSV) and infectious mononucleosis syndrome (CMV and EBV) 3, 5, 6 . Clinical manifestations of VZV infection are chickenpox or varicella (primary infection) and shingles (reactivation) 3 . In immunocompromised persons such as transplant recipients, patients with malignant diseases and HIV-infected patients, herpesviruses can cause severe, sometimes fatal disease 7, 8 . In this population group, common clinical symptoms include retinitis, pneumonitis, hepatitis, esophagitis, meningitis and encephalitis 1, 9 . It has been documented that hemodialysis patients have impaired immune response, which predisposes them to herpesvirus infections. Infections in these patients may be due to a primary infection or, more commonly, by reactivation of latent virus or reinfection with exogenous virus (CMV) 10, 11 . Th ere are many published studies on the prevalence of herpes group viruses in the general population; however, there are few recent data on hemodialysis patients.
Th e aim of this study was to analyze the prevalence of herpes group viruses in the Croatian patients with end-stage renal disease undergoing chronic hemodialysis.
Subjects and Methods
During a three-year period (2013-2015), 152 consecutive serum samples from hemodialysis patients were tested for the presence of HSV-1/2, VZV, CMV and EBV IgM and IgG antibodies at two large Croatian medical institutions (Croatian Institute of Public Health and Zagreb University Hospital Center). Control group included 150 asymptomatic persons presenting for routine testing (antenatal screening, couples undergoing medically assisted reproduction, or elective preoperative check-up) with no symptoms of acute febrile disease. Th e mean age of hemodialysis patients was 53.4±14.5 (range 20-78) years, whereas the mean age of control subjects was 46.1±13.2 (range 19-87) years.
Serologic tests were performed using a commercial enzyme-linked immunosorbent assay (ELISA) (Sekisui Virotech, Rüsselsheim, Germany) or enzymelinked immunofl uorescent assay (ELFA) (Vidas; Biomerieux, Marcy l'Etoile, France). VZV, CMV and EBV IgM/IgG positive samples were further tested for IgG avidity using ELISA (Euroimmun, Lübeck, Germany) for confi rmation of recent infection. HSV-1/2 IgM/IgG positive samples were confi rmed using a western blot test (Euroimmun, Lübeck, Germany).
Statistical analysis
Seroprevalence rates were expressed with 95% confi dence intervals (CI). Diff erences between groups were compared using c 2 of Fisher exact test. Th e strength of association between outcomes (seropositivity to herpesviruses) and potential risk factors (hemodialysis, gender, age and setting) was assessed using multiple logistic regression: adjusted odds ratios and 95%CI are presented. Statistical analysis was performed using STATA/IC ver. 14.1 (StataCorp LP, USA). Th e level of statistical signifi cance was set at p<0.05.
Results
Th e overall prevalence of IgG and IgM antibodies to herpes group viruses in hemodialysis patients and control subjects is presented in Table 1 a,b. Hemodialysis patients showed signifi cantly higher CMV IgG seropositivity compared to controls (88.2% vs. 78.7%, p=0.011). Although higher HSV-1 (85.5% vs. 80.0%, p=0.054) and VZV (99.3% vs. 96.0%, p=0.051) seroprevalence rates were also recorded in hemodialysis patients, these diff erences did not reach statistical signifi cance. Th e prevalence of HSV-2 and EBV was similar in both groups (12.5% vs. 12.7%, p=0.137, and 98.0% vs. 95.3%, p=0.113, respectively). Acute VZV infection (IgM positive) was detected more commonly in the control group (4.7% vs. 0.7%, p=0.029). Th ere was no diff erence in the prevalence of other herpesvirus infections between patients on hemodialysis and control subjects: HSV-1 0% vs. 2.0%, p=0.121; HSV-2 1.3% vs. 0%, p=0.252; CMV 2.0% vs. 0.7%, p=0.253; and EBV 2.6% vs. 2.0%, p=0.278. Using IgG avidity, recent primary CMV and EBV infection was detected in two control group subjects. In all other IgM/IgG positive hemodialysis patients and control subjects, IgG antibodies of high avidity were detected indicating recurrent infection.
Th e IgG seropositivity to herpes group viruses according to participant characteristics is presented in Tables 2 and 3 . Th ere was no diff erence in IgG seropositivity between genders. According to age, a sharp increase in CMV prevalence was observed in hemodialysis group, from 62.5% in patients aged less than 30 years to 90.5% in patients aged 31-39 years; thereafter the prevalence remained stable (83.9%-92.9%). In the control group, seroprevalence was bimodal with an increase in seropositivity from 46.7% in <30 age group to 71.1% in 31-40 age group and from 72.4% in 41-50 age group to 95.2% in 51-60 age group. High preva-lence rates of VZV and EBV were found in all age groups in both hemodialysis patients and control group (98.5-100% vs. 96.4-100%, and 87.5-100% vs. 89.5-100%, respectively). HSV-1 seroprevalence was stable in diff erent age groups among hemodialysis patients (83.9-88.9%), whereas in control subjects it increased progressively by the age of 40 years (53.3-93.1%) and remained stable thereafter. In hemodialysis patients, HSV-2 seropositivity was highest in the youngest age group (25.0%) and varied from 4.8% to 16.7% in other age groups. In the control group, an increase in seropositivity was found starting from 31-40 group to 51-60 group (7.9%-21.4%) (Fig. 1) . Th ere was no diff erence in seropositivity between the residents of urban and rural areas.
Results of logistic regression (Table 4) showed older age to be a signifi cant predictor for CMV and EBV IgG seropositivity (increase in age by one year: CMV OR=1.055; 95%CI=1.030-1.080; and EBV OR=1.075, 95%CI=1.023-1.130).
Discussion
Th e results of this study showed a signifi cantly higher CMV seropositivity rate in hemodialysis patients compared to healthy subjects (88.2% vs. 78.7%), which is similar to the results of an earlier Croatian study (2010-2012; 90.7% vs. 81.9%) 12 . Similar results have been reported from German (83.0% vs. 63.7%-73.9%) and Turkish (99.6% vs. 82.9%) studies 13, 14 , whereas in a Dutch study, the percentage of CMV seropositive hemodialysis patients (68.7%) was in the range of the prevalence reported in the general population 15 . A higher prevalence among hemodialysis patients could be explained by the acquisition of CMV through repeated blood transfusions or exposure to CMV through contaminated equipment during hemodialysis procedure.
Although this study found higher seroprevalence rates of HSV-1 and VZV in hemodialysis patients, these diff erences were not signifi cant (HSV-1 85.5% . Seroprevalence rates in Croatian hemodialysis patients were high in all age groups (HSV-1 83.9%-88.9% and VZV 98.5%-100%). Similar VZV seropositivity was noted in some other countries such as Th e Netherlands where 97.9% of transplant recipients and 96.8% of pre-transplant patients were found to be seropositive 17 . In Scotland, hemodialysis patients showed a similar seroprevalence of 98.8%
18 . An Iranian study found a very high overall VZV seropositivity (97.9%), with a signifi cant diff erence between age groups: 88.8% in patients aged <40 years, 98.2% in patients aged 41-55 and 100% in patients aged >56 years 19 . Th e prevalence of HSV-2 was similar in both tested groups in our study (hemodialysis 12.5% and controls 12.7%). Studies from other countries showed a wide range of HSV-2 prevalence among hemodialysis patients, from 5.4% in Iran 20 to 29% in Kosovo 21 . In addition, a Kosovo study found that hemodialysis patients had about a three-fold greater higher risk of being HSV-2 seropositive than blood donors 21 . Our study showed EBV to be highly prevalent in both hemodialysis patients (98.0%) and adult healthy population (95.3%). Two Iranian studies addressed the prevalence of EBV infection in hemodialysis patients. A study conducted from 2005 to 2008 showed 100% EBV seropositivity in both potential renal transplant donors and transplant recipients 22 . A more recently published study (2011) showed a higher, although not statistically signifi cant diff erence in EBV IgG seroprevalence between re-transplant patients (70%) and kidney donors (52%) 23 .
Th e present study found no signifi cant diff erence in herpes group virus seroprevalence between genders, which is similar to the results of many other studies conducted in hemodialysis patients [23] [24] [25] . However, a slightly higher CMV seroprevalence in women was noted in some studies 26 , whereas a Sudanese study has reported a slightly higher seroprevalence in men (97.9% vs. 93.3%) 27 . Our results showed that older age was a signifi cant predictor for CMV and EBV seropositivity. Age-related increase in the seroprevalence of CMV/EBV antibodies has also been shown in some studies 15 , whereas others found a higher, but not signifi cant diff erence in seropositivity in older patients 26 . In contrast, studies from Urmia (Iran) and Gezira (Sudan) showed no relationship of age with CMV seroprevalence 27, 28 . In conclusion, results of this study indicate that herpes group viruses are widely distributed in Croatia. Being on hemodialysis is a signifi cant risk factor for CMV seropositivity. In addition, older age is a significant predictor for both CMV and EBV seropositivity. 
